Roth Affirms Rexahn (RNN) at 'Buy' Following FY14 Results; Supinoxin, RX-3117 Remain in Focus
Tweet Send to a Friend
Roth Capital affirms Rexahn Pharmaceuticals (NYSE: RNN) at Buy with a price target of $3 following FY14 results announced earlier ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
